会议通知|全球再生医学研发创新与类器官研究峰会2024
ATMP 系列峰会持续专注全球细胞与基因治疗领域,始终坚持从全球视角出发,促进来源于中国的高质量研发创新, 快速推进先进治疗产品的研发与商业化进程,探索全球合作新模式。近年来 ATMP2019-2023 汇聚了来自宾夕法尼亚大学、纪念斯隆-凯特琳癌症中心、MD 安德森癌症中心、帕克癌症免疫疗法研究所、美国费城儿童医院、加州大学、美国国立癌症研究所、美国国立卫生研究院、新加坡科技研究局、日本京都大学iPS 细胞研究所等众多国际先进疗法先驱,及中国顶尖学府、科研院所及知名产业界嘉宾的共同参与。由迪易生命科学主办的 ATMP2024 第七届先进疗法创新峰会与全球再生医学研发创新与类器官研究峰会将于2024年5月9日-10日在北京龙城温德姆酒店召开。扫码注册全球再生医学研发创新与类器官研究峰会 2024类器官在疾病建模,抗癌药物筛选,药物毒理检测,还有基因和细胞疗法的应用并做出了重大贡献。类器官将用于模拟更复杂的器官,模拟器官内相互作用,并探索致病机制。为促进探索神经发育、神经表观遗传、3D类脑器官、诱导性多能干细胞、神经和精神类疾病模型、肿瘤类器官在免疫治疗中的应用,类器官模型在长寿医学领域的研究, 视网膜类器官疾病模型,单细胞组学等众多研究方向;探讨合作新模式。第七届先进疗法创新峰会 - 全球再生医学研发创新与类器官研究峰会将于2024年5月9-10日在北京举办。主要议题:- 3D人脑类器官-神经科学与脑科学的最新研究进展- 人脑类器官在神经发育疾病中的研究- 精准治疗时代 - 肿瘤类器官在免疫治疗中的应用- 3D细胞培养与类器官;器官芯片助力疾病建模 - 再生医学- 干细胞与脏器类器官研究 ( 脑科学、神经科学、眼科-视网膜、呼吸道-肺成体、肝胆、肿瘤与器官芯片)- 干细胞技术与类器官模型在长寿医学领域的研究进展及应用前景- 视网膜类器官疾病模型与视网膜再生医学- 神经退行性疾病的干细胞疗法 - 类器官芯片,生物传感器与疾病模型主旨演讲嘉宾 Plenary Speakers宋洪军著名华人神经科学家美国国家医学院院士美国宾夕法尼亚大学佩雷尔曼医学院再生医学研究所演讲主题: Therapeutic Application of Human 3D Brain Organoids: Opportunities and ChallengesAbstract: Brain organoids are 3D tissue cultures that resemble cell type diversity, tissue architecture and developmental trajectory of the native human brain tissues. Rapid advances in the stem cell technologies have led to human pluripotent stem cell-derived brain organoids that mimic the development and properties of different regions of the developing human brain. In parallel, brain organoids have been generated from patient surgical tissues, such as glioblastoma, that can maintain inter- and intra-tumor heterogeneity as well as the tumor microenvironment. I will review recent development of brain organoid technologies and provide examples for therapeutic applications of these human stem cell-derived brain organoids, such as applications during the past two global pandemics (Zika virus and SARS-Cov2). I will also discuss technologies of tumor organoids and their applications in the personized medicine. Finally, I will discuss challenges ahead. 罗振革 上海科技大学生命科学与技术学院执行院长演讲主题: Applications and Optimization of Human Brain OrganoidsAbstract: Understanding the fundamental processes of human brain development and diseases is of great importance for our health. However, the translational potency for the knowledge obtained using traditional animal models remains limited due to species differences in the aspects of brain cytoarchitecture. Over the past years, an emerging model, the “brain organoid” integrated from human pluripotent stem cells, has been developed to mimic developmental processes of the human brain and disease-associated phenotypes to some extent, making it possible to better understand the complex structures and functions of the human brain. In this talk, I will present the applications of brain organoids in the understanding of human brain development and diseases, as well as our efforts put into brain organoid optimization, in particular vascularization.尚小云茂行生物创始人兼首席执行官重庆国际免疫研究院副院长演讲主题: Gene Editing - Innovative Allogeneic CAR T-Cell Therapy for Intracranial Solid Tumors, 3D Human Brain OrganoidsAbstract: Intracranial tumors have poor prognosis, high recurrence rate and no standard treatment. This presentation will focus on how to overcome the critical issues of limited efficacy and high cost of conventional therapies in the treatment of malignant solid tumors. Mainly introduces the important innovations achieved by allogeneic CAR-T cell therapy in the treatment of intracranial solid tumors, through the advanced CRISPR gene editing technology and continuous optimization of cell therapy processes. We have successfully solved the core problems of allogeneic CAR-T cells in the treatment of solid tumors, such as rejection, poor efficacy and insufficient persistence, significantly reducing treatment costs and providing patients with more diverse and efficient treatment options.李晨钟 香港中文大学校长讲席教授演讲主题: 生物传感器和器官/类器官芯片的一体化Abstract: Biosensor is a powerful, label-free technique allowing us to perform analysis of molecular interactions in real-time. SPR spectroscopy can address questions such as specificity of an interaction, dissociation and association rate constants binding kinetics, binding affinity, and concentrations of selected molecules present in a sample of interest. In this work, we report the novel SPR based cell/organoid integrated sensing platforms that allow us to real-time monitor cell and 3D tissue activities upon various of stimulations. Using the novel set up, we measured and compared the binding affinity of vascular endothelial growth factor (VEGF) to vascular endothelial growth factor receptor (VEGFR) and VEGF to bevacizumab. Results have shown that bevacizumab binds VEGF with a higher association rate and affinity compared to VEGFR. Further, this platform has been employed to mimic the in vivo condition of the VEGF–VEGFR angiogenic switch. Competitive binding to VEGF between VEGFR and bevacizumab was monitored in real-time using this platform. The present invention provides surface plasmon resonance (SPR) based sensing systems and methods for rapid, sensitive, and real-time analysis of analyte secretion from living cells. In one embodiment, the SPR based sensing device of the present invention comprises at least one cell culture module for culturing living cells, wherein the cell culture module is configured so that analytes secreted from the living cells can be released onto a SPR sensing surface. The SPR based sensing system can perform a real-time analysis of one or more analytes secreted from the living cells by including a coating on the SPR sensing surface. In addition, we have successfully demonstrated the use of surface plasmon resonance (SPR) technology to characterize the contractility of 3D cardiac tissues in response to Blebbistatin and ATP drug exposure in real time.金子兵首都医科大学教授附属北京同仁医院北京市眼科研究所演讲主题: Human Retinal Organoids for Disease Modeling & RegenerationAbstract: Together with the rapid advancement of retinal organoid technology, human induced pluripotent stem cell have enabled us to generated patient-specific retina tissue. In this talk, I will introduce the retinal organoid differentiation, disease modeling, and transplantation.刘兴国中国科学院广州生物医药与健康研究院研究员中国科学院再生生物学重点实验室研究员演讲主题: Stem Cell and Organoid Model for Aging and DiseasesAbstract: Aging in mammals is accompanied by an imbalance of intestinal homeostasis and accumulation of mitochondrial DNA (mtDNA)mutations.However, little is known about how accumulated mtDNA mutations modulate intestinal homeostasis. We observe the accumulation of mtDNA mutations in the small intestine of aged male mice, suggesting an association with physiological intestinal aging. Using polymerase gamma (POLG)mutatormice and wild-type mice, we generate male mice with progressive mtDNA mutation burdens. Investigation utilizing organoid technology and in vivo intestinal stem cell labeling reveals decreased colony formation efficiency of intestinal crypts and LGR5-expressing intestinal stem cells in response to a threshold mtDNA mutation burden. Mechanistically, increased mtDNA mutation burden exacerbates the aging phenotype of the small intestine through ATF5 dependent mitochondrial unfolded protein response (UPRmt) activation. This aging phenotype is reversed by supplementation with the NAD+ precursor, NMN. Thus, we uncover a NAD+ dependent UPRmt triggered by mtDNA mutations that regulates the intestinal aging.刘鹏清华大学医学院生物医学工程系研究员,博导昌平国家实验室新发突发传染病部领衔科学家演讲主题: 肿瘤类器官在免疫治疗中的应用Application of Tumor Organoids in ImmunotherapyAbstract: Immune checkpoint blockade (ICB) opens the new era of cancer treatment, yet the heterogeneous nature of immune cells and their diverse spatial distributions demand novel techniques to decipher the local tumor immune microenvironment (TIME) to expand the patient groups benefiting from ICB. Here we generate primary lung cancer organoids (pLCOs) by isolating the tumor cell clusters, including the infiltrating immune cells, from dissected lung cancer samples. A FascRNA-seq platform allowing both the phenotypic evaluation and the scRNA-seq of all the single cells in an organoid was developed to dissect the TIME in individual pLCOs. Our analysis on 171 individual pLCOs derived from 7 patients revealed that pLCOs retained the fundamental features as well as the intra-tumor heterogeneity of local TIME in the parenchyma of parental tumor tissues, providing a series of models with the same genetic background but various TIME. Linking the single cell transcriptome data of individual pLCOs with their responses to ICB allowed us to confirm the central role of CD8+ Ts in ICB induced antitumor immunity, to identify the potential tumor-reactive T cells with a set of 10 genes, and to unravel the factors regulating T cell activity.向阳飞上海科技大学助理教授,研究员博士生导师演讲主题: Development and Application of Human Neural OrganoidsAbstract: Neural organoids are in vitro three-dimensional models that mimic the human brain or other structures of the nervous system. Beginning with stem cells, neural organoids are formed through unguided or guided neural differentiation under three-dimensional suspension culture conditions, relying on cell="text-indent:2em "张婷吉美瑞生创始人兼首席执行官陈丽娟跃赛生物首席运营官盛健神曦生物首席执行官演讲主题:In-situ Neuro-regenerative Gene Therapy: from Bench to BedsideAbstract: 1. Background information of In-situ neuro-regenerative gene therapy2. NeuExcell cutting-edge platform and pipeline progress: bench to bedside3. Team introduction and partnership郭炜神济昌华联合创始人兼首席科学官演讲主题: AAV-Based Gene Therapy Strategies for Neurological Diseases周静敏鲸奇生物联合创始人兼首席执行官演讲主题: The Progress on Genemagic’s Key Pipeline – Parkinson’s Diseaseext-indent:2em "北恒生物联合创始人兼首席科学官杨林博生吉创始人董事长兼首席执行官张同存波睿达创始人董事长兼首席执行官吕璐璐合源生物首席执行官刘华星华生物董事长兼首席科学家况娇森朗生物首席医学官演讲主题: Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBLAbstract: CD7 is a transmembrane glycoprotein highly expressed in T-cell acute lymphob